Daiichi Sankyo Belgium

What we do: Daiichi Sankyo Belgium is a pharmaceutical company dedicated to creating and delivering innovative therapies that improve healthcare standards worldwide. The company focuses primarily on oncology and cardiovascular health, leveraging advanced science and technology to meet diverse patient needs. As part of the global Daiichi Sankyo group, it contributes to the development and marketing of pharmaceutical products aimed at enhancing patient care.

Location: The company is headquartered at Boulevard de France 3-5, 1420 Braine-l'Alleud, Belgium, serving as a key affiliate within the European network of Daiichi Sankyo.

History: Daiichi Sankyo Belgium operates under the umbrella of Daiichi Sankyo Europe GmbH, which was formed in 2006 through the merger of the Japanese companies Daiichi and Sankyo. The global group has a rich legacy of over 100 years in pharmaceutical science, with European roots dating back to the 1980s. The Belgian entity benefits from this extensive heritage and global expertise.

Organization & culture: With a dedicated workforce of 54 employees across 13 countries, Daiichi Sankyo Belgium fosters a collaborative and agile environment. The company values courage, collaboration, and continuous improvement, encouraging open communication and active contribution from all team members. This culture empowers employees to make a significant impact in advancing healthcare.

Recent developments: While no specific recent product launches or awards are noted, the company aspires to set the benchmark for customer centricity in Europe by 2020 and aims to be a competitive player in oncology, reflecting its strategic focus and commitment to innovation.